Expiry of Listed Options
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company reported that a significant number of options lapsed unexercised, while the exercised options have strengthened its cash position ahead of an upcoming Phase III trial analysis for a cannabidiol product. CEO Dr. Paul Gavin highlighted the positive impact of this outcome on the company's financial health and its plans for future commercial activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Avecho Biotechnology Limited on 6ix
Earlier from Avecho Biotechnology
- March 2026 Quarterly Activities Report & Appendix 4C
- Avecho completes recruitment for Phase III interim analysis
- Annual Report 31 December 2025
- December 2025 Quarterly Activities Report & Appendix 4C
- Phase III CBD Clinical Trial Recruitment Update
Later from Avecho Biotechnology
- Avecho completes treatment for Phase III interim analysis
- Receipt of Research & Development Tax Incentive
- Positive interim results from Phase III insomnia program
- Positive interim analysis advances Avecho Phase III insomnia program
- June 2026 Quarterly Activities Report & Appendix 4C
Follow Avecho Biotechnology into a list and get an email when it puts out news.
Follow Avecho Biotechnology